Long-term outcomes and pretreatment immune profiling of perioperative toripalimab plus FLOT in gastric or gastroesophageal junction adenocarcinoma: a phase II trial
Year: 2026
Type: preprint
Study design: Clinical Trial
Abstract: Long-term outcomes after perioperative immunochemotherapy for resectable gastric or gastroesophageal junction (G/GEJ) adenocarcinoma remain incompletely characterised. In this single-arm phase II trial (NCT04354662), 51 patients with locally advanced G/GEJ received toripalimab plus fluorouracil, leucovorin, oxaliplatin and docetaxel before surgery with postoperative treatment were enrolled. The reported co-primary endpoints were primary-tumour pathological complete response and 3-year DFS. With median follow-up of 63.1 months, primary-tumour complete response was 19.6% (10/51), whereas nodal-inclusive ypT0N0 response was 13.7% (7/51). Three-year DFS was 52.9% (95% CI, 38.5%-65.5%), 5-year OS was 59.0% (42.9%-71.9%). Grade ≥3 reported treatment-related adverse events occurred in 72.5% of patients. Pretreatment biopsies from 24 patients underwent multiplex immunofluorescence. Higher stromal CD3 positivity was nominally associated with longer survival after median dichotomization, but continuous-variable associations were nonsignificant and no feature survived false-discovery-rate correction. Findings support independent investigation of stromal CD3 positivity but establish neither comparative benefit nor biomarker validity.
Source: Research Square
Language: English
Subfield: Oncology
Field: Medicine
Domain: Health Sciences
Open Access status: green
OpenAlex ID: W7236640433
